ImmunoDiagnostics FGF-21 is a metabolic hormone mainly produced in liver. It regulates glucose and lipid metabolism through pleiotropic actions in multiple tissues, and protects against metabolic damages under various stresses.
In humans, high circulating FGF21 levels are found in obesity and multiple cardiometabolic disorders, including metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease and coronary artery disease. Serum FGF21 is a potential biomarker for the early detection and risk prediction of these diseases.
Recombinant full-length mouse FGF-21 expressed in E.Coli.
Rabbit specific IgG was purified by mouse FGF-21 affinity chromatography.
The antibody detects circular mouse FGF-21.
Solution in PBS, azide free.
Store at -20°C. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.
This antibody can be used at 2µg/ml with the appropriate secondary reagents to detect mouse FGF-21.
This antibody can be used at 0.2µg/ml to 0.5µg/ml with the appropriate secondary reagents to detect mouse FGF-21.
Fibroblast growth factor 21(FGF-21) is a novel protein that has been implicated in the regulation of lipid and glucose metabolism under fasting and ketotic conditions. In murine models, FGF-21 is predominantly expressed in liver, but it also expressed in adipose tissue and pancreatic β-cells. FGF-21 stimulates glucose uptake in adipocytes. It also protects animals from diet-induced obesity when overexpressed in transgenic mice and lowers blood glucose and triglyceride levels when administered to diabetic rodents. When administered daily for 6 weeks to diabetic rhesus monkeys, FGF-21 caused a dramatic decline in fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon. Furthermore, elevated plasma FGF-21 concentrations in humans appear to be related to the presence of hepatic and peripheral insulin resistance.
Search this site for “ImmunoDiagnostics”